Aim To compare the effect of indocyanine green (ICG)-assisted internal limiting membrane (ILM) peeling and triamcinolone acetonide-assisted posterior vitreous removal on visual acuity in patients with diffuse diabetic macular oedema (DMO). Methods In total, 24 patients with diffuse DMO who underwent pars plana vitrectomy were included in this study. In all, 11 patients (mean age 57 years) were performed ICGassisted ILM peeling; while 13 patients (mean age 54 years) underwent triamcinoloneassisted posterior vitreous removal. Patients from two different treatment regimens were compared in terms of best-corrected visual acuity (BCVA) at postoperative sixth months. Results In ICG-assisted ILM peeling group, preoperative BCVA (1.370.4, mean7SD, logMAR) improved postoperatively to 0.970.5 (P ¼ 0.011). In eyes underwent triamcinoloneassisted posterior vitreous removal, baseline BCVA of 1.470.4 improved to 1.070.5 (P ¼ 0.007). There was no difference between baseline as well as postoperative sixth-month BCVA results of both groups (P ¼ 0.59 and P ¼ 0.57, respectively). Conclusions Triamcinolone-assisted posterior vitreous removal and ICG-assisted ILM peeling have the same effect in terms of postoperative BCVA in patients with diffuse DMO.
Introduction
Diabetic Macular Oedema (DMO) is common cause of visual loss in diabetics. The treatment is based mainly on laser photocoagulation but results are unsatisfactory. 1 Intravitreal triamcinolone injection have been successfully tried for DMO. However, the need for reinjections and various complications are the main obstacles. 2 The role of vitreoretinal traction in the pathogenesis of DMO as well as positive impact of vitrectomy and removal of internal limiting membrane (ILM) on DMO has been known. [3] [4] [5] [6] Triamcinolone-assisted posterior vitreous separation is also beneficial for DMO. 7, 8 We compared the efficacy of indocyanine green (ICG)-assisted ILM peeling and triamcinolone-assisted posterior vitreous separation in terms of best-corrected visual acuity (BCVA) in DMO.
Materials and methods
In total, 24 type II Diabetes Mellitus patients with diffuse DMO who underwent pars plana vitrectomy were evaluated retrospectively. Signed informed consent was obtained from the patients. The patients were randomly assigned into two groups: 11 patients (5 female) with a mean age of 57 years (range 48-64) underwent ICG-assisted ILM peeling; while 13 patients (6 female) with a mean age of 54 years (range, 47-61) underwent triamcinolone-assisted posterior vitreous removal. Diffuse DMO was the main surgical indication for all patients that had been suffering from significant loss of vision within last 6 months. 
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examination. Fundus photographs and fluorescein angiography were obtained when needed. At least 3 months before the operation, patients had laser treatment, failed to achieve fluid absorption, and additional laser treatment was not advised. Patients with tractional macular detachment, dense vitreous haemorrhage, and posterior vitreous detachment were excluded. Preoperative and postoperative 6-month BCVA examination results were analysed.
During operation, either 0.1 ml of ICG 0.25% or 0.5-1.0 ml of triamcinolone acetonide (40 mg) was used as a surgical adjunct. Intraoperative scatter laser photocoagulation was performed in all eyes.
Pre-and postoperative 6-month logMAR BCVA values were compared with Mann-Whitney and Wilcoxon tests. 
Results

Discussion
Prospective studies reported 43% 6 and 52% 5 of eyes with DMO gained two or more lines of visual acuity following ILM peeling. Performing vitrectomy without ILM peeling in eyes with no evident vitreomacular traction, LaHeij et al 3 reported resolution of DMO in 21 of 21 eyes while Tachi and Ogino 4 reported resolution of DMO in 57 of 58 eyes. These favourable results make ILM removal be questionable. ICG staining facilitates and accelerates ILM peeling but a potential toxic effect of ICG should be kept in mind. 9 Haritoglou et al 10 detected visual field defects after ICG staining during vitrectomy. By removing ILM, we can be sure of releasing tractional forces on the macula. As ILM plays an important role as a scaffold for proliferating astrocytes, the removal of the ILM may prevent the development of epiretinal membranes after vitrectomy for DMO.
11
A certain number of eyes with DMO did not have visual recovery even after a successful vitrectomy. 7 Diabetic eyes had a greater chance of having a residual vitreous cortex after posterior vitreous removal, as demonstrated by the triamcinalone-assisted vitrectomy. 6 Failure to recognise true posterior vitreous hyaloid may contribute to continued morbidity after vitrectomy. Residual vitreous on the retina left untreated during vitrectomy may serve as a scaffold for continued neovascular proliferation and release inflammatory mediators leading to complications of proliferative diabetic retinopathy. 6 The triamcinoloneassisted vitrectomy provides better removal of the posterior vitreous cortex. 7 We believe that ILM peeling provides complete removal of macular tractions and vitreous remnants after surgical posterior vitreous separation acting as an inflammatory focus. Therefore, if triamcinolone-assisted posterior vitreous separation is performed, then ILM removal may not be needed. This study showed that, triamcinolone-assisted posterior vitreous removal and ICG-assisted ILM peeling have the same effect on BCVA in DMO, but further studies with large number of cases and longer follow-up time may better clarify the efficacy of these techniques for functional outcome.
